Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mayne Pharma GroupMAYNF 52 Debt-to-EBITDA is 0.51 as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 90 Medical Distribution companies, Mayne Pharma Group ranks better than 65.56% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Mayne Pharma Group's Debt-to-EBITDA or its related term are showing as below:
MAYNF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -20.66 Med: -1.28 Max: 1.69
Current: 1.44
During the past 13 years, the highest Debt-to-EBITDA Ratio of Mayne Pharma Group was 1.69. The lowest was -20.66. And the median was -1.28.
MAYNF's Debt-to-EBITDA is ranked better than 65.56% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs MAYNF: 1.44
Mayne Pharma Group (OTCPK:MAYNF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Mayne Pharma Group Debt-to-EBITDA Related Terms
Mayne Pharma Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Mayne Pharma Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Mayne Pharma Group (MAYNF) has a Debt-to-EBITDA of 0.51 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mayne Pharma Group. According to the industry distribution chart, Mayne Pharma Group ranks #31 out of 90 companies in the Medical Distribution industry, placing it in the top 34.4%.
Is Mayne Pharma Group's Debt-to-EBITDA too high?
Mayne Pharma Group's current Debt-to-EBITDA is 0.51. The Medical Distribution industry median Debt-to-EBITDA is 2.45. Mayne Pharma Group's value of 0.51 is 79.2% below this industry median. Based on the distribution chart, Mayne Pharma Group ranks #31 out of 90 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Debt-to-EBITDA compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #31 out of 90 companies for Debt-to-EBITDA. This puts Mayne Pharma Group in the upper half of its industry. The industry median Debt-to-EBITDA is 2.45. Mayne Pharma Group's value of 0.51 is 79.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current Debt-to-EBITDA of 0.51 is 79.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mayne Pharma Group. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Debt-to-EBITDA is 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.70, compared to a current price of $1.97 — trading 46.7% below its estimated fair value. The current Debt-to-EBITDA is 0.51 and 79.2% below the Medical Distribution industry median of 2.45. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Debt-to-EBITDA is 0.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $1.97 is trading 46.7% below its estimated GF Value™ of $3.70.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Debt-to-EBITDA: 0.51
GF Value™: $3.70 vs. price of $1.97 (46.7% below fair value)
Industry Position: 79.2% below the Medical Distribution median (#31 of 90)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score
Get the complete analysis for MAYNF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
